Overview
Maija Risteli practices practicing medicine in Oulu, Finland.
Ms. Risteli is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Tongue Cancer, Oral Squamous Cell Carcinoma, and Head and Neck Squamous Cell Carcinoma (HNSCC).
She is actively involved in clinical research, co-authoring 22 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Maija Risteli
Is Maija Risteli a top-rated expert for Tongue Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Maija Risteli is classified as an Advanced expert for Tongue Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Maija Risteli participate in research or clinical trials?
Yes. Maija Risteli has published 22 articles and abstracts on conditions like Tongue Cancer. You can view a list of Maija Risteli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Tongue CancerMs. Risteli isAdvanced. Learn about Tongue Cancer.
- Experienced
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Oral Squamous Cell CarcinomaMs. Risteli isExperienced. Learn about Oral Squamous Cell Carcinoma.